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Objective: To evaluate trends in mortality among adults with myeloid leukemia in the Vale
do  Paraíba, State of São Paulo.
Methods: Data from the Brazilian National Health Service database DATASUS provided the
number of deaths caused by myeloid leukemia and the number of inhabitants per year in
the  Regional Health Division XVII from 1994 to 2011. Registries were categorized according to
gender into four age ranges (over 20 years, 20–49, 50–69 and over 70 years) for an estimation
of  the annual percent change for age-adjusted mortality rates. The percent changes were
calculated using the Joinpoint regression analysis model.
Results: Overall, a signiﬁcant decline per year was demonstrated for the entire sample (over
20  years) across the 18-year period studied (annual percent change: −5.59%; 95% CI: −8.5 to
−2.5%  for males; p-value < 0.05 and −7.02%; 95% CI −11.2 to −2.8% for females; p-value < 0.05)
with  no signiﬁcant difference between genders. In an analysis using two  Joinpoints, sig-
niﬁcant drops were observed from 1994 to 2001 (annual percent change: −21.22%; 95%
conﬁdence interval: −27.9 to −13.9%; p-value < 0.05) and from 1994 to 2003 (annual per-
cent change: −12.86%; 95% conﬁdence interval −22.2 to −2.5%; p-value < 0.05) for men  and
women, respectively. The declining trends were greatest for patients aged over 70 years
with  the age-adjusted mortality rates in younger groups declining non-signiﬁcantly except
for  males aged 50–69 years old.
Conclusion: Our data suggest a signiﬁcant decline per year in age-adjusted mortality rates of
adult patients diagnosed with myeloid leukemia from 1994 to 2011 in the Vale do Paraíba,
State of São Paulo.
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to −2.5%) for men  and women respectively (Figure 3). The
declining trends were greatest for patients aged over 70 years
old with the age-adjusted mortality rates in younger groups
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Figure 1 – Estimated crude mortality rate (per 100,000
inhabitants) according to age range and gender. Data are
expressed as mean ± standard deviation (error bars).8  rev bras hematol he
Introduction
It is widely accepted that the assessment of mortality data is
a useful tool for monitoring outcomes in patients with hema-
tologic malignancies, particularly in countries where survival
estimates from cancer registries are not broadly available.1,2
This information may be relevant to the strategic planning of
health managers and enable the implementation of measures
to improve services that treat these kinds of diseases.
Myeloid leukemia is a group of hematologic malignan-
cies divided into acute and chronic subtypes, some of which
require expensive treatment regimens while others are poten-
tially lethal. In Brazil, the Ministry of Health has demonstrated
the mortality rates for leukemia in general3 but there are
insufﬁcient data to support discussions regarding death rates
from myeloid leukemia.
Therefore, in order to provide comprehensive and region-
alized information which reﬂect the characteristics and needs
of the local population, an exploratory analysis of the mortal-
ity trends due to myeloid leukemia was performed in the Vale
do Paraíba, State of São Paulo.
Methods
This study was carried out in the Centro de Hematologia do
Vale (CHV). The CHV consists of medical oncohematologi-
cal professionals from the following services: Pio XII Hospital
in São José dos Campos and the Regional Hospital of the
Vale do Paraíba, located in the city of Taubaté. These non-
teaching hospitals are referral centers of the Regional Health
Division XVII, composed of 39 municipalities in the Vale do
Paraíba. They have treated patients with hematologic malig-
nancies under the Brazilian National Health Service (SUS)
since early 1999. Together, the services that comprise the CHV
attend all adult SUS patients diagnosed with acute myeloid
leukemia (AML) and more  than 110 patients with chronic
myeloid leukemia (CML).
Data from the SUS database, DATASUS (Health Informa-
tion, TABNET, statistical data), available on the Brazilian
Ministry of Health website4 were considered for inclusion
in the analysis. Registries from the Regional Health Division
XVII (Vale do Paraíba), provided the number of deaths per
year due to myeloid leukemia (categorized as C92 according
to the International Classiﬁcation of Diseases 10 [ICD-10]
from 1996 to 2011 and as 205 according to ICD-9 from 1994
to 1995). This classiﬁcation comprises the following diseases:
AML, CML, subacute myeloid leukemia, acute promyelocytic
leukemia (APL), acute myelomonocytic leukemia, myeloid
leukemia otherwise speciﬁed and myeloid leukemia not
otherwise speciﬁed. To obtain a set of data with adequately
speciﬁed characteristics, registries were grouped according
to gender into seven age ranges: 20–29, 30–39, 40–49, 50–59,
60–69, 70–79 and more  than 80 years. Registries (Health Infor-
mation, TABNET, demographic and socioeconomic data) also
provided the number of residents per year according to the
above-mentioned age ranges and the 2000 standard million
population; thus the death rates per 100,000 inhabitants
were calculated (crude mortality rate). These groups werer. 2 0 1 5;3  7(1):7–11
compared using the one-way analysis of variance (ANOVA),
and Kruskal–Wallis test with Dunn’s multiple comparisons
test. p-values less than 0.05 were considered statistically sig-
niﬁcant. The annual percent change (APC) of the age-adjusted
mortality rates based on the 2000 standard million population
was also estimated by ﬁtting a straight-line regression to the
natural logarithm of the rates, with calendar year used as a
regressor variable in Joinpoint regression analysis5 using the
Joinpoint Regression Program (version 4.0.4).6 The APC were
considered signiﬁcant when the 95% conﬁdence intervals
(95% CI) excluded zero (p-value < 0.05). In order to compare the
data, the same method was adapted to perform APC analysis
of age-adjusted mortality rates among patients with myeloid
leukemia from all regions of Brazil.
Results
The crude mortality rate rose as the age increased with this
phenomenon being observed equally in men  and women;
similar crude mortality rates were found between 20 and 49
years, 50 and 69 years and over 70 years (Figure 1). Based on
these initial ﬁndings, data were categorized according to gen-
der into four age ranges (over 20, 20–49, 50–69 and over 70
years) for the APC estimation of age-adjusted mortality rates.
Overall, signiﬁcant declines per year in the age-adjusted mor-
tality rates were demonstrated for the entire sample (over 20
years) across the 18-year period studied (APC: −5.59%; 95% CI:
−8.5 to −2.5% for males; p-value < 0.05 and APC: −7.02%; 95%
CI: −11.2 to −2.8% for females; p-value < 0.05); no signiﬁcant
difference was found between the genders (Figure 2). In an
analysis performed with two Joinpoints, signiﬁcant declines
were observed from 1994 to 2001 (APC: −21.22%; 95% CI: −27.9
to −13.9%) and from 1994 to 2003 (APC: −12.86%; 95% CI: −22.2Similar values were  observed for the 20- to 49-year age
group, 50- to 69-year age group and over 70-year age group
(Kruskal–Wallis test with Dunn’s multiple comparisons
test).
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Figure 2 – Trends in age-adjusted mortality rate for over
20-year-old males and females from 1994 to 2011.
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Figure 3 – Signiﬁcant changes over successive time
segments (Joinpoints) for over 20-year-old males and
females from 1994 to 2011.
Table 1 – Estimated annual percent change of the
age-adjusted mortality rates of patients with myeloid
leukemia according to age range and gender in the Vale
do Paraíba from 1994 to 2011.
Age range (years) Male Female
Over 20 −5.59 (−8.5 to −2.5)a −7.02 (−11.2 to −2.8)a
20–49 −2.40 (−5.8 to 1.1) −3.60 (−7.3 to 0.1)
50–69 −3.90 (−7.2 to −0.5)a −0.30 (−3.7 to 3.3)
Over 70 −6.52 (−10.3 to −2.6)a −8.01 (−13.2 to −2.5)a
Data are expressed as mean rate of change (%) and (95% conﬁdence
interval).
a p-value < 0.05.
Table 2 – Estimated annual percent change of the
age-adjusted mortality rates of patients with myeloid
leukemia according to age range in Brazil from 1994 to
2011.
Age range (years) Mean annual
percent change
95% conﬁdence
interval
Over 20 +1.4a +0.6 to +2.2
20–49 −1.2a −1.9 to −0.6
50–69 +0.3 −0.4 to +1.0
Over 70 +2.3a +1.4 to +3.1a p-value < 0.05.
declining albeit not signiﬁcantly except for males aged 50–69
years old (Table 1). With regard to Brazil as a whole, a signiﬁ-
cant upward trend was observed for both the entire sample
(over 20 years) and for patients aged over 70 years. There
was a signiﬁcant decline for patients aged 20–49 years and an
insigniﬁcant increase for patients aged 50–69 years (Table 2).
Discussion
SUS is available to all Brazilian citizens although roughly 25%
of the population has private health insurance7; we  therefore
believe that data extrapolated from the DATASUS database
are useful for clinical and epidemiological studies. However,
an important limitation of this study regards the quality of
data. Registration of erroneous ICD codes results in misclassi-
ﬁcation and could be responsible for differences in mortality
rates observed in this series. It should also be stressed that,
in many  areas, access to timely cancer care is impaired by
the inadequate infrastructure of the healthcare system, espe-
cially in low-income and geographically isolated populations
with these cases being more  likely to remain unreported than
cases treated in hospitals. In addition, deaths from patients
with either acute or chronic myeloid leukemia are registered
in the DATASUS database as myeloid leukemia which is unsa-
tisfactory because mortality rates vary between acute and
chronic myeloid leukemia. This complicates comparisons and
in particular makes it difﬁcult to interpret regional differ-
ences. Furthermore, the study was based on a cross-sectional
structure and registries did not state whether deaths occurred
during or after speciﬁc treatments, therefore a cause-effect
relationship could not be established. Thus, an exploratory
and comparative analysis was done to report the mortality
mote
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rates and the results gained over a period of time in the Vale
do Paraíba.
The diagnosis of AML  may explain, at least in part, the
increased crude mortality rates observed in the elderly group.
AML  presents at all ages, but its incidence increases with
age and outcomes are strongly age and performance status
dependent. Older patients have more  comorbidities and a
higher incidence of poor prognostic factors, such as secondary
leukemia and high-risk cytogenetics. Moreover, early death
rates of 15% to 55% have been reported among the elderly and
even in cases of APL, a lower survival rate has been described
in older patients.8,9
Overall, our series suggests that mortality dropped signif-
icantly over the years in this region. The possible reasons for
this ﬁnding are based on the improvements in the quality of
care which was introduced by our team in the Vale do Paraíba
since early 1999; the practice guidelines for the use of antimi-
crobial agents in neutropenic patients with cancer, hospital
environmental precautions, more  intensive chemotherapy
followed by autologous hematopoietic stem cell transplan-
tation (which has been used in this region since 2004) and
allogeneic bone marrow transplant from related or unre-
lated donors probably led to better survival of these patients.
Besides, new treatment options such as the use of all-trans
retinoic acid (ATRA) plus chemotherapy, which was associated
with a high complete remission rate in newly diagnosed APL,
and the use of anti-tyrosine kinase targeted therapy speciﬁc
for the BCR-ABL rearrangement in CML  (authorized in Brazil
since October, 2001) could also explain the observed decrease
in mortality. On the other hand, our ﬁndings contrast with
the upward trend in mortality seen in Brazil as a whole. We
believe that different Brazilian regions also have experienced
improvements however, there is still a biased allocation of
resources, underinvestment in equipment and infrastructure
and inequities in cancer care across population groups; some
institutions provide all aspects of health care to speciﬁc popu-
lations while others are excluded which consequently reﬂects
on the mortality rates observed in Brazil.
The age-adjusted mortality rates in younger groups
declined insigniﬁcantly over the last few years. Furthermore,
a striking ﬁnding of the present study is that the decrease
was the greatest for over 70-year-old patients contrasting with
those observed for the same age group in Brazil. This sce-
nario is difﬁcult to explain. It has been demonstrated that
patients who were diagnosed with AML  at younger ages have
higher survival rates,10 and CML  is expected in this age range.
Based on these reasons and considering the aforementioned
improvements in the quality of care in this region, we expected
to ﬁnd a more  signiﬁcant drop across time in the younger
groups. It is possible that a signiﬁcant decline could not
be demonstrated for younger patients because death rates
were consistently low over the years. Moreover, in another
study regarding demographic characteristics of hematological
malignancies in the Vale do Paraíba,11 it was demonstrated
that the period between the ﬁrst symptoms and deﬁnitive
diagnosis of the disease in this age range was greater than
two months in 65% of the cases; a delay in receiving a proper
diagnosis which consequently worsens the chances of suc-
cessful chemotherapy may explain these ﬁndings. With regard
to older patients, improvements in early death rates and longr. 2 0 1 5;3  7(1):7–11
term survival were demonstrated even in older patients with
AML9; the fall in mortality rates with advancing age points to
an increase in the quality of care, suggesting that old patients
may be receiving optimal treatment for their conditions in this
region.
Finally, the drop in cancer mortality is not surprising. The
American Cancer Society recently demonstrated that cancer
death rates have declined 20% over the last 20 years in the
United States.2 In addition, authors have reported an asso-
ciation between socioeconomic status and mortality due to
cancer in different regions of the world.12–15 In this context,
the Vale do Paraíba has made great strides due to the economic
and social development of the population, including territorial
expansion and industrialization. The present work suggests
that our combined and continuous efforts to make better and
sustained improvements in the quality of cancer care con-
tributed to the decrease in myeloid leukemia mortality rates
across the 18-year period studied.
Conclusion
Despite the methodological limitations, the data of this study
suggest a signiﬁcant decline in age-adjusted mortality rates of
patients diagnosed with myeloid leukemia from 1994 to 2011
in the Vale do Paraíba, State of São Paulo.
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